Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-01 16:41 • The Motley Fool Positive Axe Cap view: Selective

The article compares two financial sector ETFs: iShares MSCI Europe Financials ETF (EUFN) and iShares U.S. Regional Banks ETF (IAT). EUFN offers higher dividend yield (4.1%), lower volatility, and stronger 5-year returns ($2,637 vs $1,105), making it ideal for conservative income investors. IAT provides lower expense ratio (0.37%) and concentrated U.S. regional bank exposure but carries higher volatility and smaller AUM. The choice depends on whether investors prefer European financial diversification or U.S. regional banking focus.

Axe note: European financials ETF EUFN offers steadier income and lower risk than US regional bank ETF IAT, with clear trade-offs for rand-based investors.

2026-10-01 16:30 • The Motley Fool Positive Axe Cap view: Neutral

Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

Axe note: Royalty Pharma offers diversified drug royalties but has limited local relevance for JSE investors.

2026-10-01 16:27 • The Motley Fool Positive Axe Cap view: Selective

Synopsys stock jumped 12.5% after announcing at its Investor Day that it expects revenue to grow up to 15% to $11.2 billion in 2027, exceeding analyst expectations of $11 billion. The company projects a 20.7% operating profit margin and non-GAAP margins averaging 44%. The article discusses the valuation debate between GAAP earnings (P/E of 58x) versus non-GAAP earnings (P/E of 25.4x), with free cash flow metrics supporting the non-GAAP valuation at approximately 25x FCF.

Axe note: Synopsys’ upbeat 2027 revenue and profit guidance sent shares sharply higher despite valuation debates.